StreetAlpha
13F holdings · Q3 2026

Deep Track Capital

Greenwich, CT · files as Deep Track Capital, LP
Know the moment Deep Track Capital filesYou follow Deep Track Capital An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1856083

Deep Track Capital reported 71 stocks worth $5.9B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are GH (8.4%), BMRN (6.4%) and IMVT (5.2%). Compared with Q2 2026, the fund opened new positions in INSM, LTGO and BBIO, added to BMRN, TARS and VERA, trimmed GH, IMVT and MANE and sold out of ALNY, IONS and CYTK.

Latest filing: what Deep Track Capital did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
18 new17 added18 trimmed13 sold outBought about $1.2B · sold about $1.6B
New 18
See all 18 →
Added 17
See all 17 →
Trimmed 18
  • GH−$105M−17%
  • GRAL−$102M−40%
  • ORKA−$71.3M−44%
  • DFTX−$66.6M−64%
  • MBX−$64M−63%
See all 18 →
Sold out 13
  • ALNY$248M
  • Nuvalent Inc$220M
  • IONS$174M
  • Atai Beckley NV$76M
  • CYTK$59.6M
See all 13 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$5.9B−12.5% vs last quarter · $6.1B including options
Stocks held7118 new · 13 sold out
Top 5 weight29.0%spread out
Turnover47%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
GH
Guardant Health Inc
$500M8.4%2.8M−588K (−17%)8 of 8
2
BMRN
Biomarin Pharmaceutical Inc
$382M6.4%6.4M+3.1M (+93%)5 of 8
3
IMVT
Immunovant Inc
$309M5.2%9.2M−180K (−2%)8 of 8
4
TARS
Tarsus Pharmaceuticals Inc
$299M5.0%3.8M+140K (+4%)7 of 8
5
MANE
Veradermics Inc
$230M3.9%1.9M−100K (−5%)3 of 8
6
VERA
Vera Therapeutics Inc
$226M3.8%7M+3M (+75%)4 of 8
7
PCVX
Vaxcyte Inc
$200M3.4%3.5M−787K (−18%)7 of 8
8
ALKS
Alkermes PLC
$182M3.1%4.5M+500K (+13%)4 of 8
9
OCUL
Ocular Therapeutix Inc
$168M2.8%21.9M+2.3M (+11%)8 of 8
10
UTHR
United Therapeutics Corp Del
$163M2.7%300K+176K (+143%)2 of 8
🔒 61 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
ALNY
Alnylam Pharmaceuticals Inc
$248M825K
NUVALENT INC
$220M1.8M
IONS
Ionis Pharmaceuticals Inc
$174M2.2M
ATAI BECKLEY NV
$76M14.4M
CYTK
Cytokinetics Inc
$59.6M700K

🔒 Free account: see all 13.

Options

valued at the underlying shares
StockTypeValueSharesChange
GMAB
Genmab A/s
Call$98.5M2.8M−240,000
TEM
Tempus AI Inc
Call$81.9M1M+1,000,000
DYN
Dyne Therapeutics Inc
Call$16.1M1M+1,000,000

Reported value

last 8 quarters
$2.7BQ4 '24
$3.1BQ1 '25
$3.1BQ2 '25
$3.6BQ3 '25
$4.4BQ4 '25
$4.8BQ1 '26
$6.8BQ2 '26
$5.9BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Deep Track Capital 13F FAQ

What does Deep Track Capital own?

Deep Track Capital reported 71 stocks worth $5.9B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are GH (8.4%), BMRN (6.4%) and IMVT (5.2%). The table above lists every position in the filing (the top 10 without an account).

What did Deep Track Capital buy and sell in Q3 2026?

Compared with Q2 2026: 18 new positions, 17 added to, 18 trimmed and 13 sold out. New positions include INSM, LTGO and BBIO. It sold all of ALNY, IONS and CYTK.

When will Deep Track Capital file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Deep Track Capital's portfolio worth?

The Q3 2026 filing reports $5.9B in US stocks ($6.1B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.